Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Actas Dermosifiliogr ; 106 Suppl 1: 87-95, 2015 Nov.
Artículo en Español | MEDLINE | ID: mdl-26895943

RESUMEN

Requests for fillers or dermatological implants have dramatically increased in dermatology consultations in the last few years, either for the correction of superficial age-related wrinkles and cutaneous creases or to increase the volume of specific areas (cheeks, lips...). Dermatologists are often the first professionals to provide these treatments. Nevertheless, in other situations, the patients have already been treated, and many of them do not know the type of material that has been implanted or may even deny previous treatment, even when evident on clinical examination. In these occasions, cutaneous ultrasound is an effective and reliable tool for the real-time diagnosis of the kind of implant that has been used, its location, and the study of its possible complications.


Asunto(s)
Rellenos Dérmicos/administración & dosificación , Ultrasonografía , Dermatología/métodos , Humanos , Derivación y Consulta , Envejecimiento de la Piel/efectos de los fármacos
2.
Am J Emerg Med ; 19(2): 130-3, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11239257

RESUMEN

The objective was to evaluate both the effectiveness and safety of urapidil in management of hypertensive emergencies (HE) in the prehospital setting. This was an open, prospective study for 6 months. We evaluated systolic (SBP), diastolic (DBP), and mean blood pressure (MBP), and heart rate (HR) with continuous noninvasive hemodynamic monitoring in 16 consecutive cases of HE. We used urapidil at different doses (25 to 100 mg) at 5 minute intervals, according to the blood pressure response. The basal DBP was 127 +/- 16 mmHg. Urapidil was effective in 15 patients. ANOVA test showed a significant drop out in DBP (P <.0001) and HR (P <.004). The highest decrease was obtained in the first 10 minutes. The decrease in DBP and HR values were significant at 5 minutes versus basal (P <.05) and at 10 versus 5 minutes (P <.01). All adverse effects had little relevance. Urapidil is effective and safe in management of HE when used by a medical team in the prehospital setting.


Asunto(s)
Antagonistas Adrenérgicos alfa/administración & dosificación , Antihipertensivos/administración & dosificación , Servicios Médicos de Urgencia , Hipertensión/tratamiento farmacológico , Piperazinas/administración & dosificación , Antagonistas Adrenérgicos alfa/efectos adversos , Anciano , Análisis de Varianza , Femenino , Hemodinámica/efectos de los fármacos , Humanos , Hipertensión/etiología , Masculino , Proyectos Piloto , Piperazinas/efectos adversos , Estudios Prospectivos , Edema Pulmonar/complicaciones , España , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA